ReviewBrain & spine2025
Potential applications of focused ultrasound for spinal cord diseases: a narrative review of preclinical studies.
Review in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monitoring Autonomic Tone During Spinal Cord Neuromodulation Using Wearable AURIS Sensor.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focused ultrasound (FUS) technology provides unique advantages as a therapy targeting the central nervous system (CNS). We aimed to investigate and summarize the potential applications of FUS in the context of spinal cord diseases. Search strategies were created using a combination of keywords and standardized index terms. Searches were run in April 2025 in the Ovid Cochrane Central Register of Controlled Trials, EBSCO MegaFILE, Ovid Embase, Ovid Medline, Ovid PsycINFO, Scopus, and Web of Science Core Collection to retrieve all relevant studies from inception until 2024. A narrative and comprehensive summary of the current body of evidence was performed. Current preclinical studies indicate the potential use of spinal cord FUS in blood-spinal cord barrier (BSCB) disruption, neuromodulation, and inflammatory regulation following spinal cord injury. Targeted CNS drug delivery with BSCB disruption using FUS has proven promising in the context of neuro-oncology and neurotrauma. Additionally, FUS has been explored for neuromodulation in managing neuropathic pain and spasticity. FUS to the spinal cord may also provide anti-inflammatory effects and alter the local cellular response to injury. While therapeutic FUS ablation of brain structures has been extensively studied, research on similar applications within the spinal cord was less prevalent and faces multiple challenges. FUS is a highly promising technique with multiple advantages and potential applications in the treatment of spinal cord diseases. Current research efforts have shifted focus towards translational studies, while human trials are currently limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.